Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Shimada

Showing results (891-900 of 894) with videos related to

Pageof 90
Sort By:
You have reached the last page of results.This site can display upto 894 results.
Journal of Gastroenterology|June 1, 1996
Therapeutic effect of secretin in patients with jaundice; double-blind placebo-controlled multicentric trialY Fukumoto, K Okita, T Kodama, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2017
Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapyM Friedlander, J Rau, C K Lee, et al.
The Pharmacogenomics Journal|January 25, 2007
Exploratory aspirin resistance trial in healthy Japanese volunteers (J-ART) using platelet aggregation as a measure of thrombogenicityT Fujiwara, M Ikeda, K Esumi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2016
Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcomaK Matsuo, Y Takazawa, M S Ross, et al.
Pageof 90

Showing results (891-900 of 894) with videos related to

Sort By:
Pageof 90
You have reached the last page of results.This site can display upto 894 results.
Journal of Gastroenterology|June 1, 1996
Therapeutic effect of secretin in patients with jaundice; double-blind placebo-controlled multicentric trialY Fukumoto, K Okita, T Kodama, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2017
Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapyM Friedlander, J Rau, C K Lee, et al.
The Pharmacogenomics Journal|January 25, 2007
Exploratory aspirin resistance trial in healthy Japanese volunteers (J-ART) using platelet aggregation as a measure of thrombogenicityT Fujiwara, M Ikeda, K Esumi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2016
Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcomaK Matsuo, Y Takazawa, M S Ross, et al.
Pageof 90